Part of a comprehensive analysis of the Human Biomedical Research Act 2015
All Parts in This Series
Analysis of Key Provisions in Part 1 of the Human Biomedical Research Act 2015
The Human Biomedical Research Act 2015 (HBRA) is a pivotal statute in Singapore that governs the ethical conduct and regulatory oversight of human biomedical research. Part 1 of the HBRA sets out foundational provisions that delineate the scope of research activities subject to regulatory review, particularly focusing on the role of the institutional review board (IRB) in assessing risk and consent requirements. This analysis examines the key provisions within Part 1, their purposes, and the rationale underpinning these regulatory measures.
Institutional Review Board’s Assessment of Minimal Risk Research
"Where the institutional review board is satisfied that the human biomedical research or use of the human tissue (as the case may be) involves no more than minimal risk to the research subject or donor and involves no procedures for which written consent is ordinarily required outside of a research context (for therapeutic or diagnostic purposes)." — Section 1, Human Biomedical Research Act 2015
Verify Section 1 in source document →
This provision empowers the IRB to evaluate whether a proposed research project or use of human tissue qualifies as involving "no more than minimal risk." The term "minimal risk" is critical because it establishes a threshold below which the regulatory burden may be reduced. The provision also highlights that the research must not involve procedures that would ordinarily require written consent outside the research context, such as therapeutic or diagnostic interventions.
Purpose: The rationale behind this provision is to ensure that research involving human subjects or their tissues is conducted with appropriate safeguards, while also allowing for streamlined review processes for low-risk studies. By focusing on minimal risk, the Act balances the need to protect research subjects with the practicalities of facilitating valuable biomedical research that poses little harm.
Confidentiality and Consent Form as the Sole Link to Research Subjects
"Where the institutional review board is satisfied that the only record linking the research subject and the human biomedical research or use of the human tissue (as the case may be) is or will be the consent form and the principal risk to the research subject or donor is the potential harm resulting from the unauthorised disclosure of confidential information such as the research subject’s identity and the fact of the subject’s participation in the research." — Section 1, Human Biomedical Research Act 2015
Verify Section 1 in source document →
This provision addresses scenarios where the only identifiable link between the research subject and the research is the consent form itself. The principal risk identified here is the unauthorized disclosure of confidential information, including the subject’s identity and participation status.
Purpose: This clause underscores the importance of confidentiality in human biomedical research. It recognizes that even when physical or procedural risks are minimal, the breach of confidentiality can cause significant harm to subjects. Hence, the IRB must ensure that adequate measures are in place to protect sensitive information, reflecting the ethical principle of respect for persons and their privacy.
Absence of Definitions, Penalties, and Cross-References in Part 1
Notably, Part 1 of the HBRA does not provide specific definitions, penalties for non-compliance, or cross-references to other Acts. This absence suggests that Part 1 serves primarily as an introductory or procedural framework, setting out the IRB’s evaluative criteria rather than substantive legal obligations or sanctions.
Purpose: The lack of definitions within Part 1 indicates that the Act likely relies on definitions provided elsewhere or assumes common understanding of terms such as "minimal risk" and "consent." Similarly, the omission of penalties and cross-references in this Part suggests that enforcement mechanisms and inter-Act relationships are addressed in subsequent Parts of the HBRA or other related legislation. This structural approach allows Part 1 to focus on guiding the IRB’s initial assessment without conflating it with enforcement or definitional complexities.
Why These Provisions Exist
The provisions in Part 1 exist to establish a clear, ethical, and practical framework for the oversight of human biomedical research in Singapore. The IRB’s role as gatekeeper ensures that research involving human subjects or tissues is conducted responsibly, with risks minimized and confidentiality safeguarded. By delineating criteria for minimal risk and consent requirements, the Act facilitates research that can advance medical knowledge while protecting individual rights and welfare.
Moreover, emphasizing confidentiality reflects Singapore’s commitment to upholding privacy in biomedical research, recognizing that the unauthorized disclosure of personal information can have profound consequences. The procedural focus of Part 1 allows for flexibility and clarity in the IRB’s decision-making process, setting the stage for more detailed regulatory provisions elsewhere in the HBRA.
Conclusion
Part 1 of the Human Biomedical Research Act 2015 establishes foundational principles for the ethical review of human biomedical research in Singapore. By empowering the institutional review board to assess minimal risk and confidentiality concerns, it ensures that research subjects and donors are protected while enabling valuable scientific inquiry. The absence of definitions, penalties, and cross-references in this Part reflects its role as a procedural guide rather than a comprehensive regulatory section. Understanding these provisions is essential for researchers, IRB members, and legal practitioners navigating the biomedical research landscape in Singapore.
Sections Covered in This Analysis
- Section 1, Human Biomedical Research Act 2015
Source Documents
For the authoritative text, consult SSO.